Lenvatinib (E7080) - Moligand™, ≥99% , Inhibitor of fms related receptor tyrosine kinase 4;Inhibitor of kinase insert domain receptor, CAS No.417716-92-8, Inhibitor of fms related receptor tyrosine kinase 4;Inhibitor of kinase insert domain receptor

CAS: 417716-92-8 Cat. No.: L125518 Peso molecular: 426.85 Número EC: 970-217-1

GRADE & PURITY Moligand™, ≥99%

Synonyms

LENVATINIB [MI] | UNII-EE083865G2 | AS-16203 | LEV | NSC800781 | NSC-800781 | DB09078 | AKOS021983298 | LENVATINIB [INN] | AKOS015838040 | BCP9000633 | DTXSID30182868 | 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

Storage

Store at -20°C,Argon charged

Shipped In

Ice chest + Ice pads

Descripción general

Lenvatinib (E7080) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β. Phase 3.

Lenvatinib is an orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF and SCF receptors.

Specifications

Sinónimos

LENVATINIB [MI] | UNII-EE083865G2 | AS-16203 | LEV | NSC800781 | NSC-800781 | DB09078 | AKOS021983298 | LENVATINIB [INN] | AKOS015838040 | BCP9000633 | DTXSID30182868 | 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

Especificaciones y pureza

Moligand™, ≥99%

Condiciones de almacenamiento de almacenamiento

Store at -20°C, Argon charged

Enviado en

Ice chest + Ice pads

Este producto requiere envío en cadena de frío. Los servicios terrestres y otros servicios económicos no están disponibles.

Grado

Moligand™

Tipo de acción

INHIBITOR

Mecanismo de acción

Inhibitor of fms related receptor tyrosine kinase 4;Inhibitor of kinase insert domain receptor

Pureza

≥99%

Nombres e identificadores

• Pubchem Sid: 488196334
• Pubchem Sid Url: https://pubchem.ncbi.nlm.nih.gov/substance/488196334
• Sonrisas canónicas: COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl
• IUPAC Name: 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide
• InChIKey: WOSKHXYHFSIKNG-UHFFFAOYSA-N
• INCHI: 1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)
• Isómeros SMILES: COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl
• CAS alternativo: 417716-92-8
• Términos de entrada MeSH: 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide;4-(3-chloro-4-((cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide;4-(3-chloro-4-(N'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxami
• Peso molecular: 426.85
• Reaxy-Rn: 12096874
• Reaxys-RN_link_address: https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=12096874&ln=

Taxonomic Classification

Taxonomy Tree

• Kingdom Organic compounds
  • Superclass Organoheterocyclic compounds
    • Clase Quinolines and derivatives
      • Subclass Quinoline carboxamides

• Kingdom: Organic compounds
• Superclass: Organoheterocyclic compounds
• Clase: Quinolines and derivatives
• Subclass: Quinoline carboxamides
• Intermediate Tree Nodes: Not available
• Direct Parent: Quinoline carboxamides
• Alternative Parents: Diarylethers N-phenylureas Phenoxy compounds Anisoles Alkyl aryl ethers Chlorobenzenes Pyridines and derivatives Aryl chlorides Heteroaromatic compounds Ureas Primary carboxylic acid amides Azacyclic compounds Hydrocarbon derivatives Carbonyl compounds Organic oxides Organochlorides Organonitrogen compounds Organopnictogen compounds
• Molecular Framework: Aromatic heteropolycyclic compounds
• Substituents: Quinoline-6-carboxamide - Diaryl ether - N-phenylurea - Phenoxy compound - Anisole - Phenol ether - Alkyl aryl ether - Halobenzene - Chlorobenzene - Aryl chloride - Aryl halide - Monocyclic benzene moiety - Pyridine - Benzenoid - Heteroaromatic compound - Carboxamide group - Primary carboxylic acid amide - Carbonic acid derivative - Urea - Azacycle - Carboxylic acid derivative - Ether - Organonitrogen compound - Organooxygen compound - Organic oxygen compound - Organic nitrogen compound - Carbonyl group - Hydrocarbon derivative - Organic oxide - Organopnictogen compound - Organochloride - Organohalogen compound - Aromatic heteropolycyclic compound
• Descripción: This compound belongs to the class of organic compounds known as quinoline carboxamides. These are quinolines in which the quinoline ring system is substituted by one or more carboxamide groups.
• External Descriptors: aromatic ether - quinolines - ureas - monocarboxylic acid amide - cyclopropanes - monochlorobenzenes - aromatic amide

Data sources

1. Djoumbou Feunang Y, Eisner R, Knox C, Chepelev L, Hastings J, Owen G, Fahy E, Steinbeck C, Subramanian S, Bolton E, Greiner R, and Wishart DS. ClassyFire: Automated Chemical Classification With A Comprehensive, Computable Taxonomy. Journal of Cheminformatics, 2016, 8:61.

DOI: 10.1186/s13321-016-0174-y

Mecanismos de acción

Referencias

1. Mengming Xia, Xueyi Song, Zebei Lu, Yu Wang, Quan Zhou, Peiwu Geng, Shuanghu Wang, Yunfang Zhou, Qingjun Wu, Aixia Han.  (2023)  Evaluation of the inhibitory effect of azoles on pharmacokinetics of lenvatinib in rats both in vivo and in vitro by UPLC-MS/MS.  Thoracic Cancer,  14  (33): (3331-3341).  [PMID:37771131] [10.1111/1759-7714.15125]

2. Jie Yao, Shuming Tang, Chenyan Shi, Yunzhi Lin, Lanlan Ge, Qinghua Chen, Baoru Ou, Dongyu Liu, Yuyang Miao, Qiujie Xie, Xudong Tang, Jia Fei, Guangyi Yang, Jun Tian, Xiaobin Zeng.  (2022)  Isoginkgetin, a potential CDK6 inhibitor, suppresses SLC2A1/GLUT1 enhancer activity to induce AMPK-ULK1-mediated cytotoxic autophagy in hepatocellular carcinoma.  Autophagy,      [PMID:36048765] [10.1080/15548627.2022.2119353]

3. Peisen Zheng, Yiqun Xia, Xin Shen, Hui Lu, Yinghua Chen, Chenxin Xu, Chenyu Qiu, Yafei Zhang, Peng Zou, Ri Cui, Xiaoying Huang.  (2024)  Combination of TrxR1 inhibitor and lenvatinib triggers ROS-dependent cell death in human lung cancer cells.  International Journal of Biological Sciences,      [PMID:38164168] [10.7150/ijbs.86160]

4. Yilan Huang, Siwei Wang, Xiaojun Zhang, Chen Yang, Sikai Wang, Hongxia Cheng, Aiwu Ke, Chao Gao, Kun Guo.  (2024)  Identification of Fasudil as a collaborator to promote the anti-tumor effect of lenvatinib in hepatocellular carcinoma by inhibiting GLI2-mediated hedgehog signaling pathway.  PHARMACOLOGICAL RESEARCH,      [PMID:38280440] [10.1016/j.phrs.2024.107082]

5. Jie Yao, Haoqiang Wan, Jingmei Zhang, Wanying Shen, Xiaofang Wei, Chenyan Shi, Baoru Ou, Dongyu Liu, Lanlan Ge, Jia Fei, Xiaobin Zeng.  (2024)  Tubuloside B, a major constituent of Cistanche deserticola, inhibits migration of hepatocellular carcinoma by inhibiting Hippo-YAP pathway.  PHYTOMEDICINE,      [PMID:38552378] [10.1016/j.phymed.2024.155552]

6. Mengmeng Dong, Yumeng Liu, Yuting Xiao, Qingqing Wu, Mingjing Guan, Zunqiang Xiao, Junwei Liu, Lidong Cao, Yi Lu.  (2025)  Tumor-Targeted PLGA Nanospheres Enhance Therapeutic Effect of Lenvatinib in Hepatocellular Carcinoma via Photothermal and Photodynamic Therapy.  ACS Applied Materials & Interfaces,      [PMID:40689931] [10.1021/acsami.5c09045]

7. Ruoxin Tu, Yining Wang, Ru Xu, Shusheng Wang, Jiabin Cai, Lin Sun, Pengfei Gao.  (2025)  The CCR5/ROS/NRF2 axis Mediates Dihydrotanshinone I-Induced oxidative stress and apoptosis in hepatocellular carcinoma.  BIOCHEMICAL PHARMACOLOGY,      [PMID:40633809] [10.1016/j.bcp.2025.117119]

8. Tongge Li, Shihui Wang, Qianhui Ling, Junyi Sun, Ning Yang, Zhanglei Fu, Zhaoyuan Zhang, Si Chen, Yanfei Wang, Ni Yu, Yafei Wang, Zhexuan Ding, Haodong Liu, Yanwei Jia, Yifang Wang, Xingcai Zhang.  (2025)  Cell Viability, Drug Screening, and Mechanism Study Under Mild Phototherapy Integrated Chemotherapy (PIC).  Advanced Science,      [PMID:40883257] [10.1002/advs.202502836]

9. Huimin Xie, Lin Ma, Xiaoli He, Songsong Zhao, Jin Wang, Ao Zhu, Changming Liu, Olga Piskareva, Chao Deng, Fenghua Meng, Mi Liu.  (2025)  Elevating MHC I expression on tumor cells by nanovesicles loading tyrosine kinase inhibitors can improve the efficacy of cancer vaccines.  Frontiers in Immunology,      [PMID:41019037] [10.3389/fimmu.2025.1653533]

10. Dan Wang, Wenqi Ma, Yuanyuan Zhang, Yufeng Wang, Lei Sun, Jue Jiang, Lianying Jiao, Runqing Li, Yujie Zhang, Mingzhen Zhang, Qi Zhou.  (2024)  A versatile nanoplatform carrying cascade Pt nanozymes remodeling tumor microenvironment for amplified sonodynamic/chemo therapy of thyroid cancer.  BIOMATERIALS,      [PMID:39213978] [10.1016/j.biomaterials.2024.122778]

11. Yufeng Deng, Qi hu, Zhiying Song, Mengyuan Nie, Zhiguo Wu, Yongrong Lei, Meng Liu, Dujuan Zhan, Baogang Xie.  (2025)  Mechanism of d-Glucaro-1,4-lactone enhancing the anticancer efficacy of lenvatinib via the IFN-γ-STAT3-PD-L1 signaling pathway in hepatocellular carcinoma.  PHYTOMEDICINE,      [PMID:41485289] [10.1016/j.phymed.2025.157760]

12. Dan Wang, Lei Sun, Juan Wang, Lirong Wang, Zhongyu Wang, Yutong Zhang, Qi Zhou, Yuhang Chen, Jue Jiang.  (2026)  Versatile Nanotherapeutics for Enhancing Sonodynamic/Chemo Therapy of Thyroid Cancer through Remodeling Tumor Microenvironment and Synergistic Reactive Oxygen Species Augment.  Biomaterials Research,      [PMID:41788857] [10.34133/bmr.0338]

13. Wen Luo, Yana Ma, Weijia Zhu, Ruican Nie, Yue Wu, Dongqiu Shan, Shijun Xu, Ho-Young Song, Hongtao Hu.  (2026)  A Biomimetic Mn-Doped Polydopamine Nanoplatform for MRI-Enabled Synergistic Therapy to Enhance Lenvatinib Efficacy in Liver Cancer.  ACS Applied Materials & Interfaces,      [PMID:42003816] [10.1021/acsami.6c00228]